Related Experiment Video
Updated: Feb 10, 2026

Author Spotlight: Isolation and Culture of Primary Synovial Macrophages and Fibroblasts from Murine Arthritis Tissue
Published on: February 24, 2023
Mannan-induced Nos2 in macrophages enhances IL-17-driven psoriatic arthritis by innate lymphocytes
Jianghong Zhong1, Tatjana Scholz2, Anthony C Y Yau1
1Medical Inflammation Research, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm 171 77, Sweden.
Abstract:
Previous identification of the inducible nitric oxide synthase (NOS2) gene as a risk allele for psoriasis (Ps) and psoriatic arthritis (PsA) suggests a possible pathogenic role of nitric oxide (NO). Using a mouse model of mannan-induced Ps and PsA (MIP), where macrophages play a regulatory role by releasing reactive oxygen species (ROS), we found that NO was detectable before disease onset in mice, independent of a functional nicotinamide adenine dinucleotide phosphate oxidase 2 complex. MIP was suppressed by either deletion of Nos2 or inhibition of NO synthases with NG-nitro-l-arginine methyl ester, demonstrating that Nos2-derived NO is pathogenic. NOS2 expression was also up-regulated in lipopolysaccharide- and interferon-γ-stimulated monocyte subsets from patients with PsA compared to healthy controls. Nos2-dependent interleukin-1α (IL-1α) release from skin macrophages was essential for arthritis development by promoting IL-17 production of innate lymphoid cells. We conclude that Nos2-derived NO by tissue macrophages promotes MIP, in contrast to the protective effect by ROS.
Insights
Inducible nitric oxide synthase (NOS2) produces nitric oxide (NO), a key factor in developing psoriasis and psoriatic arthritis. Targeting NOS2 may offer new therapeutic strategies for these inflammatory skin and joint conditions.
Area of Science:
- Immunology
- Dermatology
- Rheumatology
Background:
- The inducible nitric oxide synthase (NOS2) gene is a risk factor for psoriasis (Ps) and psoriatic arthritis (PsA).
- Nitric oxide (NO) may play a pathogenic role in PsA, contrasting with the regulatory role of reactive oxygen species (ROS) from macrophages.
Purpose of the Study:
- To investigate the role of NOS2-derived NO in a mouse model of mannan-induced Ps and PsA (MIP).
- To examine NOS2 expression in patients with PsA and its contribution to disease pathogenesis.
Main Methods:
- Utilized a mouse model of mannan-induced Ps and PsA (MIP).
- Assessed NO levels and NOS2 expression in mice and PsA patient monocytes.
- Investigated the effects of Nos2 deletion and NOS inhibition on MIP development.
Main Results:
- NO was detected before disease onset in the MIP model, independent of NADPH oxidase 2.
- Nos2 deletion or NOS inhibition suppressed MIP, confirming Nos2-derived NO is pathogenic.
- NOS2 was upregulated in PsA monocytes; Nos2-dependent IL-1α release from macrophages was crucial for IL-17 production and arthritis.
Conclusions:
- Nos2-derived NO from tissue macrophages promotes PsA development in the MIP model.
- This contrasts with the protective role of ROS in this model.
- Findings highlight NOS2 as a potential therapeutic target for PsA.
Related Concept Videos
Introduction to Innate and Adaptive Immunity
Innate immunity is the body's natural, nonspecific defense system that acts quickly to protect against pathogens. It incorporates physical barriers like skin and mucous membranes and cellular elements such as phagocytes and natural killer cells. This part of our immune system provides an immediate,...
Cells of the Innate Immune Response
Phagocytes
Phagocytes police the peripheral tissues by removing cellular debris and responding to the invasion of foreign substances or pathogens. Many phagocytes attack and remove microorganisms even before lymphocytes detect them. The human body has two general...
Self-Evaluation: Self-Enhancement and Self-Verification
ATP Driven Pumps I: An Overview
There are four main types of ATP-driven pumps - P-type, V-type, F-type, and ABC transporter. All these pumps are of varying complexities and...
Bioavailability Enhancement: Drug Solubility Enhancement
Bioavailability Enhancement: Drug Permeability Enhancement

